Highest-materiality recent filing
Pasithea Therapeutics appoints Kartik Krishnan as Chief Medical Officer, effective May 1, 2026
Dr. Krishnan appointed CMO effective May 1; will lead PAS-004 clinical strategy for NF1-associated neurofibromas.
Pasithea receives Nasdaq bid price deficiency notice; 180-day cure period
Received Nasdaq notice on Feb 20, 2026 for failing minimum $1.00 bid price for 30 consecutive business days.
Authorized common stock increased from 100M to 500M shares via certificate amendment filed Jan 28, 2026.
Pasithea Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq deficiency notice on June 23, 2025 for failing $1.00 minimum bid price rule 5550(a)(2).
Pasithea raises ~$60M in public offering of common stock and pre-funded warrants
Gross proceeds of $60.0M; net proceeds of ~$54.9M after fees and expenses.
BRAF V600E melanoma patient achieved -31.9% tumor reduction on PAS-004 monotherapy; remains on trial >11 months.
Pasithea activates UAB site for Phase 1/1b PAS-004 NF1 trial; platinum sponsor of symposium
New U.S. clinical site at University of Alabama at Birmingham activated for ongoing Phase 1/1b PAS-004 trial in adult NF1 patients; enrollment starts immediately.
Pasithea Therapeutics approves new executive/director compensation and option grants at $0.715
CEO Tiago Reis Marques base salary increased to $533,000; target bonus reduced to 55%.
Pasithea activates two South Korean sites for PAS-004 NF1 trial; first patient dosed
Two sites activated: Asan Medical Centre and Severance Hospital Yonsei University Health System, both now recruiting.
Stockholders approved reverse stock split of common stock at ratio from 1:2 to 1:20, at Board discretion, valid through September 2026.
Pasithea Therapeutics sets 2025 annual meeting for Sep 3; proposal deadline Jul 21
Annual meeting set for September 3, 2025; proxy materials expected available July 24, 2025.
Pasithea Therapeutics receives Nasdaq minimum bid price non-compliance notice
Nasdaq notified company on June 23, 2025 that common stock bid price closed below $1.00 for 30 consecutive business days.
Pasithea Therapeutics upsizes ATM offering from $2.08M to $4.23M, adding $2.15M in new shares
Maximum aggregate offering price increased from $2,076,000 to $4,227,000 under November 2024 Sales Agreement with H.C. Wainwright.
Pasithea closes $5M public offering, receives $1.3M from warrant exercises
Offered 3,571,428 units at $1.40/unit (common stock or pre-funded warrant + Series C/D warrants); gross $5M.
Pasithea Therapeutics dismisses Marcum, engages CBIZ as new auditor
Marcum LLP dismissed as auditor Apr 23, 2025; CBIZ CPAs P.C. engaged for FY2025.
Pasithea enters $2.08M ATM equity facility with H.C. Wainwright
ATM agreement with H.C. Wainwright for up to $2,076,000 in common stock sales.
Pasithea Therapeutics raises $5M in private placement of pre-funded warrants and Series A/B warrants
Gross proceeds ~$5M; net proceeds ~$4.5M after fees and expenses.
No treatment-related adverse events or dose-limiting toxicities observed in first 2 cohorts (n=6); no rash or GI toxicity.
Dr. Emer Leahy elected as Class I director with 227,198 for, 27,223 withheld, 115,196 broker non-votes.
Annual meeting via internet on June 26, 2024 at 9:00 a.m. ET; record date April 29, 2024.
Pasithea regains Nasdaq minimum bid price compliance, delisting risk removed
Received Nasdaq letter on Jan 17, 2024 confirming compliance with $1.00 minimum bid price rule.
Pasithea shareholders approve classified board, supermajority vote, eliminate written consent
Stockholders approved classifying Board into three classes with staggered 3-year terms; removal only for cause.
Pasithea Therapeutics announces 1-for-20 reverse stock split effective January 2, 2024
Reverse split ratio of 1-for-20; authorized shares reduced from 495M to 100M.
Pasithea shareholders approve 2023 equity plan and reverse split authorization
Stockholders approved Pasithea 2023 Stock Incentive Plan: 2.5M shares reserved plus rollover of unused 2021 plan shares.
Pasithea Therapeutics sets 2023 annual meeting for Nov 29; shareholder proposal deadline Oct 23
Annual meeting set for November 29, 2023; proxy materials to be delivered around October 23, 2023.
Pasithea completes tender offer: buys 5.32M shares at $0.70; post-offer shares 20.8M
All 5,323,451 validly tendered shares accepted for purchase at $0.70 per share, no proration.
Pasithea Therapeutics receives Nasdaq extension to Jan 15, 2024 for bid price compliance
Nasdaq granted 180-day extension to January 15, 2024 to regain $1.00 minimum bid price compliance.
Pasithea announces $4M tender offer for common stock at $0.70/share, expected Q3 2023
Board authorized $4.0M tender offer to repurchase up to ~5.7M shares at $0.70 per share in cash.
Pasithea Therapeutics confirms no exposure to Silicon Valley Bank
Company holds no deposits or securities at Silicon Valley Bank.
Pasithea Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance
Received Nasdaq notice on Jan 19, 2023 for failure to meet $1.00 minimum bid price rule (Nasdaq 5550(a)(2)).
Pasithea settles with Camac Group; to repurchase 3.2M shares at $1.0003, standstill 3 years
Will buy back 3,205,282 shares (11% of outstanding) at $1.0003 per share (trailing 5-day VWAP).
Pasithea acquires AlloMek for $1.05M cash, 2.7M shares + warrants; adds MEK inhibitor CIP-137401
Total deal value includes $1.05M cash, 2.7M restricted shares, 1M warrants at $1.88, up to $5M milestones, and royalties.
Pasithea Therapeutics appoints Alfred J. Novak to board; two director changes
Dr. Yassine Bendiabdallah resigned from board on Sept 14, 2022, with no disagreement.
Pasithea Therapeutics files Alpha-5 Integrin financials for acquisition closed June 21, 2022
Alpha-5 (preclinical-stage, ALS/neuroinflammatory mAbs) had no revenue and $1.7M net loss for FY 2021.
Pasithea amends 8-K to extend deadline for Alpha-5 Integrin financials filing
Original 8-K filed June 22, 2022 reported acquisition of Alpha-5 Integrin, LLC.
All five director nominees elected: Tiago Reis Marques (5.79M for, 2.07M withheld), Yassine Bendiabdallah, Lawrence Steinman, Simon Dumesnil, Emer Leahy.
Pasithea Therapeutics shareholders elect directors, ratify Marcum LLP as auditor
Elected five directors: Tiago Reis Marques, Yassine Bendiabdallah, Lawrence Steinman, Simon Dumesnil, Emer Leahy for one-year terms.
Pasithea acquires Alpha-5 integrin in $3.75M stock-and-warrant deal for ALS/neurology pipeline
Pasithea acquires all equity of Alpha-5; total consideration: 3,260,870 shares of KTTA common stock at $1.15/share (11% premium to June 21 close) plus 1M warrants at $1.88 exercise price for 5 years.
Pasithea Therapeutics CFO Stanley Gloss passes away; search for replacement underway
Stanley Gloss, CFO of Pasithea Therapeutics, passed away on June 7, 2022.
Pasithea Therapeutics enters new CEO employment agreement with Tiago Reis Marques
Base salary $450,000; sign-on bonus $100,000 lump sum after Jan 1, 2022.
Pasithea Therapeutics prices $30.4M private placement of 8.68M shares and warrants at $3.50/unit.
Gross proceeds $30.4M from sale of 8.68M shares and accompanying warrants at $3.50 per unit.
On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.
Effective October 11, 2022, Daniel Schneiderman was appointed to serve as the Chief Financial Officer of the Company.
On September 14, 2022, Dr. Yassine Bendiabdallah resigned from the board of directors (the “Board”) of Pasithea Therapeutics Corp. (the “Company”).
Concurrently, the Board appointed Alfred J. Novak to the Board and to its audit committee.
On June 7, 2022, Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp. (the “Company”), passed away.
Max materiality 0.75 · Median 0.55 · Most common event other_material